`U.S. Patent 8,664,231
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`KOIOS PHARMACEUTICALS LLC
`Petitioner
`
`v.
`
`MEDAC GESELLSCHAFT FÜR KLINISCHE
`SPEZIALPRÄPARATE MBH
`Patent Owner
`____________
`
`Case IPR2016-01370
`Patent 8,664,231
`____________
`
`
`
`PATENT OWNER’S SUBMISSION OF MANDATORY NOTICE
`INFORMATION UNDER 37 C.F.R. § 42.8(a)(2)
`
`Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner medac Gesellschaft für
`
`
`
`
`
`klinische Spezialpräparate mbH submits herewith and via the Patent Trial and
`
`Appeal Board End to End (PTAB E2E) the required mandatory notice information
`
`as summarized below.
`
`REAL PARTY-IN-INTEREST
`
`The Patent Owner, medac Gesellschaft für klinische Spezialpräparate mbH,
`
`and its wholly-owned U.S. subsidiary, medac Pharma, Inc., are the real parties-in-
`
`interest.
`
`
`
`IPR2016-01370
`U.S. Patent 8,664,231
`
`
`RELATED MATTERS
`
`Patent Owner identifies the following judicial or administrative matters that
`
`would affect, or be affected by, a decision in this proceeding:
`
` Antares Pharma, Inc. v. medac Gesellschaft für klinische
`
`Spezialpräparate mbH, IPR2014-01091 (filed July 1, 2014, instituted
`
`January 6, 2015, settled April 30, 2015) (U.S. Patent 8,664,231)
`
` medac Pharma, Inc. and medac Gesellschaft für klinische
`
`Spezialpräparate mbH v. Antares Pharma, Inc., Leo Pharma A/S, and
`
`Leo Pharma Inc., 1:14-cv-01498-JBS-KMW (D.N.J., filed March 7,
`
`2014, settled April 17, 2015) (U.S. Patent 8,664,231)
`
` Frontier Therapeutics, LLC v. medac Gesellschaft für klinische
`
`Spezialpräparate mbH, IPR2016-00649 (filed February 22, 2016) (U.S.
`
`Patent 8,664,231) (Patentee; Preliminary Response filed June 2, 2016)
`
` U.S. Patent Application 14/635,542, filed March 2, 2015. The ’542
`
`application is currently pending. It published on June 18, 2015, as U.S.
`
`Patent Application Publication 2015-0164902 A1.
`
`
`
`
`
`
`
`-2-
`
`
`
`LEAD AND BACK-UP COUNSEL
`
`IPR2016-01370
`U.S. Patent 8,664,231
`
`
`Patent Owner provides the following designation of counsel:
`
`LEAD COUNSEL
`
`James F. Haley, Jr.
`Reg. No. 27,794
`ROPES & GRAY LLP
`1211 Avenue of the Americas
`New York, NY 10036-8704
`T: 212-596-9034
`F: 646-728-6231
`james.haley@ropesgray.com
`
`
`BACK-UP COUNSEL
`
`J. Steven Baughman
`Reg. No. 47,414
`ROPES & GRAY LLP
`2099 Pennsylvania Ave., NW
`Washington, DC 20006-6807
`T: 202-508-4606
`F: 202-383-8371
`steven.baughman@ropesgray.com
`
`SERVICE INFORMATION FOR PATENT OWNER
`
`Patent Owner, medac Gesellschaft für klinische Spezialpräparate mbH,
`
`consents to electronic service at IPR2016-01370_Medac@ropesgray.com. To the
`
`extent physical documents will be served on medac, please address all
`
`correspondence to lead counsel and back-up counsel at the following mailing
`
`address:
`
`ROPES & GRAY LLP
`IPRM Docketing – Floor 43
`Prudential Tower
`800 Boylston Street
`Boston, MA 02199-3600
`
`CONCLUSION
`
`Patent Owner, medac Gesellschaft für klinische Spezialpräparate mbH,
`
`-3-
`
`
`
`
`
`
`
`
`
`IPR2016-01370
`U.S. Patent 8,664,231
`
`believes this submission fulfills the requirements of 37 C.F.R. § 42.8. If additional
`
`information is required, please contact the undersigned counsel at the address
`
`shown below. The Commissioner is hereby authorized to charge any fees or costs
`
`associated with this submission and to credit any excess payments to Deposit
`
`Account No. 18-1945.
`
`
`
`Dated: August 4, 2016
`
`
`
`
`By: /James F. Haley, Jr./
`
`J. Steven Baughman (Backup Counsel)
`James F. Haley, Jr. (Lead Counsel)
`Reg. No. 47,414
`Reg. No. 27,794
`ROPES & GRAY LLP
`ROPES & GRAY LLP
`2099 Pennsylvania Ave., NW
`1211 Avenue of the Americas
`Washington, DC 20006-6807
`New York, NY 10036
`T: 202-508-4606 / F: 202-383-8371
`T: 212-596-9034 / F: 646-728-6231
`steven.baughman@ropesgray.com
`james.haley@ropesgray.com
`
`
`E-mail address for all correspondence: IPR2016-01370_Medac@ropesgray.com.
`Mailing address for all correspondence: ROPES & GRAY LLP, IPRM – Floor
`43, Prudential Tower, 800 Boylston St., Boston, MA 02199-3600
`
`Attorneys For Patent Owner
`
`
`
`
`
`-4-
`
`
`
`CERTIFICATE OF SERVICE
`
`IPR2016-01370
`U.S. Patent 8,664,231
`
`
`
`
`The undersigned certifies that the foregoing Mandatory Notice Information
`
`for inter partes Review was served by filing this document through the Patent Trial
`
`and Appeal Board End to End (PTAB E2E), as well as providing a courtesy copy
`
`via e-mail (ipr2016-01370@foleyhoag.com) to the following attorneys of record
`
`for the Petitioner listed below:
`
`Lead Counsel:
`
`Scott E. Kamholz, M.D., Ph.D., Reg. No. 48,543
`Foley Hoag LLP
`1717 K Street, N.W.
`Washington D.C. 20006-5350
`T: 202-261-7356
`F: 202-467-9656
`skamholz@foleyhoag.com
`Back-up Counsel: DeAnn F. Smith, Reg. No. 36,683
`Foley Hoag LLP
`155 Seaport Blvd.
`Boston MA 02210-2600
`T: 617-832-1230
`F: 617-832-7000
`dsmith@foleyhoag.com
`
`ipr2016-01370@foleyhoag.com
`
`Dated:
`
`August 4, 2016
`
`Respectfully submitted,
`
`
`
`
`
`
`By:
`
`/Ginny Blundell/
`
`Name: Ginny Blundell
`
`
`ROPES & GRAY LLP